Evidence map›Paper›PMID 29644339›Full record

ArticleHeliyon2018

Molecular characterization of two sub-family specific monoclonal antibodies to meningococcal Factor H binding protein.

C Lo Passo, L Zippilli, A Angiolillo, I Costa, I Pernice, R Galbo, F Felici, P T Beernink

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

C Lo PassoDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Italy.
L ZippilliDepartment of Biosciences and Territory, University of Molise, Pesche (CB), Italy.
A AngiolilloDepartment of Medicine and Health Sciences, University of Molise, Campobasso, Italy.
I CostaDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Italy.
I PerniceDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Italy.
R GalboDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Italy.
F FeliciDepartment of Biosciences and Territory, University of Molise, Pesche (CB), Italy.
P T BeerninkCenter for Immunobiology and Vaccine Development, UCSF Benioff Children's Hospital Oakland, Oakland, CA, USA.
University of Messina · ITUniversity of Molise · ITUniversity of California, San Francisco · US

Funding

The effect of binding of fH to meningococcal fHbp vaccine on antibody protectionR01AI114701 · NIAID · CHILDREN'S HOSPITAL & RES CTR AT OAKLAND · PI BEERNINK, PETER T. · 2015 to 2019
$3.3M
Improved protein-based meningococcal serogroup B vaccinesR01AI134868 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BEERNINK, PETER T. · 2018 to 2022
$3.2M
NIAID NIH HHS R01 AI114701NIAID NIH HHS R01 AI134868
6 · The paper itself

Abstract

Factor H binding protein (FHbp) is a component of two licensed vaccines for prevention of sepsis and meningitis caused by serogroup B meningococci. FHbp binds human Factor H (FH), which contributes to evasion of host immunity and FHbp sequence variants can be classified into two sub-families. Antibodies against FHbp elicit complement-mediated killing and can inhibit recruitment of FH to the bacterial surface. We report epitope mapping studies of two murine IgG mAbs, designated JAR 31 and JAR 36, isolated from a mouse immunized with FHbp in sub-family A, which is present in ∼30-40% of invasive isolates. In the present study, we tested the reactivity of mAbs JAR 31 and JAR 36 with seven natural FHbp sequence variants from different phylogenic groups. We screened bacteriophage-displayed peptide libraries to identify amino acid residues contributing to the JAR 36 epitope. Based on the reactivities of mAbs JAR 31 and JAR 36 with the seven FHbp variants, and the frequent occurrences of aspartate (D) and lysine (K) residues in the JAR 36-bound phage peptides, we selected six residues in the carboxyl-terminal region of FHbp for replacement with alanine (A). The D201A and K203A substitutions respectively eliminated and decreased binding of mAbs JAR 31 and JAR 36 to FHbp. These substitutions did not affect binding of the control mAb JAR 33 or of human FH. JAR 31 or JAR 36 mediated cooperative complement-mediated bactericidal activity with other anti-FHbp mAbs. The identification of two amino acid residues involved in the epitopes recognized by these anti-FHbp mAbs may contribute to a more complete understanding of the spatial requirements for cooperative anti-FHbp mAb bactericidal activity.

Indexed as

BiochemistryImmunologyMicrobiologyMolecular biology

Identifiers

PMID29644339
PMCPMC5889710
OpenAlexW2795628897

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.